UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 156

Sortiert nach

Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial

The Lancet (British edition), 2008-03, Vol.371 (9618), p.1073-1084

2008

Link zum Volltext

Verfügbarkeit prüfen

The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL

Cardiovascular diabetology, 2017-05, Vol.16 (1), p.66-66, Article 66

2017

Link zum Volltext

Verfügbarkeit prüfen

Treatment responses to basal insulin glargine 300U/ml and glargine 100U/ml in newly defined subphenotypes of type 2 diabetes: A post hoc analysis of the EDITION 3 randomized clinical trial

Diabetes, obesity & metabolism, 2024-02, Vol.26 (2), p.503-511

2024

Link zum Volltext

Verfügbarkeit prüfen

Recombinant Human Insulins – Clinical Efficacy and Safety in Diabetes Therapy

European Endocrinology, 2016-03, Vol.12 (1), p.12-17

2016

Link zum Volltext

Verfügbarkeit prüfen

Initiating Insulin Therapy in Type 2 Diabetic Patients Failing on Oral Hypoglycemic Agents

Diabetes care, 2009-11, Vol.32 (suppl 2), p.S260-S265

2009

Link zum Volltext

Verfügbarkeit prüfen

Treatment responses to basal insulin glargine 300 U/ml and glargine 100 U/ml in newly defined subphenotypes of type 2 diabetes: A post hoc analysis of the EDITION 3 randomized clinical trial

Diabetes, obesity & metabolism, 2024-02, Vol.26 (2), p.503-511

2024

Link zum Volltext

Verfügbarkeit prüfen

Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100 U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy

Diabetes research and clinical practice, 2017-02

2017

Link zum Volltext

Verfügbarkeit prüfen

Hypoglycaemia risk with insulin glargine 300U/mL compared with glargine 100U/mL across different baseline fasting C‐peptide levels in insulin‐naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial

Diabetes, obesity & metabolism, 2020-09, Vol.22 (9), p.1664-1669

2020

Link zum Volltext

Verfügbarkeit prüfen

Fasting C‐peptide, a biomarker for hypoglycaemia risk in insulin‐naïve people with type 2 diabetes initiating basal insulin glargine 100U/mL

Diabetes, obesity & metabolism, 2020-03, Vol.22 (3), p.315-323

2020

Link zum Volltext

Verfügbarkeit prüfen

Fasting C‐peptide, a biomarker for hypoglycaemia risk in insulin‐naïve people with type 2 diabetes initiating basal insulin glargine 100 U/mL

Diabetes, obesity & metabolism, 2020-03, Vol.22 (3), p.315-323

2020

Link zum Volltext

Verfügbarkeit prüfen

Comparative efficacy and safety of Gla‐300 versus IDegAsp in insulin‐naïve people with type 2 diabetes mellitus uncontrolled on oral anti‐diabetics

Diabetes, obesity & metabolism, 2023-09, Vol.25 (9), p.2495-2504

2023

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of basal insulin glargine 12 and 24 weeks after initiation in persons with type 2 diabetes: A pooled analysis of data from treatment arms of 15 treat-to-target randomised controlled trials

Diabetes research and clinical practice, 2014-11, Vol.106 (2), p.264-274

2014

Link zum Volltext

Verfügbarkeit prüfen

Distribution and characteristics of newly-defined subgroups of type 2 diabetes in randomised clinical trials: Post hoc cluster assignment analysis of over 12,000 study participants

Diabetes research and clinical practice, 2022-08, Vol.190, p.110012-110012, Article 110012

2022

Link zum Volltext

Verfügbarkeit prüfen

Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C‐peptide levels in insulin‐naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial

Diabetes, obesity & metabolism, 2020-09, Vol.22 (9), p.1664-1669

2020

Link zum Volltext

Verfügbarkeit prüfen

High Levels of Baseline HbA1c, FPG, and 2-Hour Postprandial Glucose Are Key Predictors for Not Achieving HbA1c < 7.0% at Six Months in People with T2DM Starting Insulin Glargine 100 U/mL

Diabetes (New York, N.Y.), 2018-07, Vol.67 (Supplement_1)

2018

Link zum Volltext

Verfügbarkeit prüfen

Response to insulin glargine 100 U/mL treatment in newly-defined subgroups of type 2 diabetes: Post hoc pooled analysis of insulin-naïve participants from nine randomised clinical trials

Primary care diabetes, 2023-08, Vol.17 (4), p.379-385

2023

Link zum Volltext

Verfügbarkeit prüfen

Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0

Diabetes, obesity & metabolism, 2019-02, Vol.21 (2), p.321-329

2019

Link zum Volltext

Verfügbarkeit prüfen

Glycaemic responses in Asian and non-Asian people with type 2 diabetes initiating insulin glargine 100 units/mL: A patient-level pooled analysis of 16 randomised controlled trials

Diabetes research and clinical practice, 2018-01, Vol.135, p.199-205

2018

Link zum Volltext

Verfügbarkeit prüfen

Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs. intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents--a randomized, prospective, crossover, open clinical trial

Health and quality of life outcomes, 2015-06, Vol.13 (1), p.77-77, Article 77

2015

Link zum Volltext

Verfügbarkeit prüfen

The emergence of biosimilar insulin preparations--a cause for concern?

Diabetes technology & therapeutics, 2012-11, Vol.14 (11), p.989

2012

Link zum Volltext

Verfügbarkeit prüfen

Hypoglycaemia risk in the first 8 weeks of titration with insulin glargine 100 U/mL in previously insulin‐naive individuals with type 2 diabetes mellitus

Diabetes, obesity & metabolism, 2018-12, Vol.20 (12), p.2894-2898

2018

Link zum Volltext

Verfügbarkeit prüfen

Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy

Diabetes research and clinical practice, 2017-02, Vol.124, p.57-65

2017

Link zum Volltext

Verfügbarkeit prüfen

Insulin glargine compared with premixed insulin for management of insulin-naïve type 2 diabetes patients uncontrolled on oral antidiabetic drugs: the open-label, randomized GALAPAGOS study

Journal of diabetes and its complications, 2015-08, Vol.29 (6), p.838-845

2015

Link zum Volltext

Verfügbarkeit prüfen

Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat‐to‐target trials with insulin glargine 100 U/mL added to oral antidiabetes agents in type 2 diabetes

Diabetes, obesity & metabolism, 2017-11, Vol.19 (11), p.1546-1554

2017

Link zum Volltext

Verfügbarkeit prüfen

Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100U/mL added to oral antidiabetes agents in type 2 diabetes

Diabetes, obesity & metabolism, 2017-11, Vol.19 (11), p.1546

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 156

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(99)
Mit Volltextzugriff
(127)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(65)
Life Sciences & Biomedicine
(52)
Humans
(32)
Male
(25)
Endocrinology & Metabolism
(24)
Female
(22)
Biological And Medical Sciences
(21)
Diabetes
(21)
Middle Aged
(17)
Animals
(16)
Insulin
(15)
Adult
(14)
Diabetes Mellitus
(14)
Aged
(13)
Insulin Glargine
(13)
Type 2 Diabetes
(13)
Medical Sciences
(12)
Biochemistry & Molecular Biology
(10)
Diabetes Mellitus, Type 2 - Drug Therapy
(10)
Physical Sciences
(10)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial

The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL

Treatment responses to basal insulin glargine 300U/ml and glargine 100U/ml in newly defined subphenotypes of type 2 diabetes: A post hoc analysis of the EDITION 3 randomized clinical trial

Recombinant Human Insulins – Clinical Efficacy and Safety in Diabetes Therapy

Initiating Insulin Therapy in Type 2 Diabetic Patients Failing on Oral Hypoglycemic Agents

Treatment responses to basal insulin glargine 300 U/ml and glargine 100 U/ml in newly defined subphenotypes of type 2 diabetes: A post hoc analysis of the EDITION 3 randomized clinical trial

Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100 U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy

Hypoglycaemia risk with insulin glargine 300U/mL compared with glargine 100U/mL across different baseline fasting C‐peptide levels in insulin‐naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial

Fasting C‐peptide, a biomarker for hypoglycaemia risk in insulin‐naïve people with type 2 diabetes initiating basal insulin glargine 100U/mL

Fasting C‐peptide, a biomarker for hypoglycaemia risk in insulin‐naïve people with type 2 diabetes initiating basal insulin glargine 100 U/mL

Comparative efficacy and safety of Gla‐300 versus IDegAsp in insulin‐naïve people with type 2 diabetes mellitus uncontrolled on oral anti‐diabetics

Efficacy and safety of basal insulin glargine 12 and 24 weeks after initiation in persons with type 2 diabetes: A pooled analysis of data from treatment arms of 15 treat-to-target randomised controlled trials

Distribution and characteristics of newly-defined subgroups of type 2 diabetes in randomised clinical trials: Post hoc cluster assignment analysis of over 12,000 study participants

Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C‐peptide levels in insulin‐naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial

High Levels of Baseline HbA1c, FPG, and 2-Hour Postprandial Glucose Are Key Predictors for Not Achieving HbA1c < 7.0% at Six Months in People with T2DM Starting Insulin Glargine 100 U/mL

Response to insulin glargine 100 U/mL treatment in newly-defined subgroups of type 2 diabetes: Post hoc pooled analysis of insulin-naïve participants from nine randomised clinical trials

Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0

Glycaemic responses in Asian and non-Asian people with type 2 diabetes initiating insulin glargine 100 units/mL: A patient-level pooled analysis of 16 randomised controlled trials

Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs. intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents--a randomized, prospective, crossover, open clinical trial

The emergence of biosimilar insulin preparations--a cause for concern?

Hypoglycaemia risk in the first 8 weeks of titration with insulin glargine 100 U/mL in previously insulin‐naive individuals with type 2 diabetes mellitus

Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy

Insulin glargine compared with premixed insulin for management of insulin-naïve type 2 diabetes patients uncontrolled on oral antidiabetic drugs: the open-label, randomized GALAPAGOS study

Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat‐to‐target trials with insulin glargine 100 U/mL added to oral antidiabetes agents in type 2 diabetes

Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100U/mL added to oral antidiabetes agents in type 2 diabetes

Suchergebnisse filtern